Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE.

Autor:	Yoshikawa S; Division of Dermatology, Shizuoka Cancer Center Hospital, Shizuoka, Japan., Kiyohara Y; Division of Dermatology, Shizuoka Cancer Center Hospital, Shizuoka, Japan., Otsuka M; Division of Dermatology, Shizuoka Cancer Center Hospital, Shizuoka, Japan., Kondou R; Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan., Nonomura C; Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan., Miyata H; Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan., Iizuka A; Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan., Ohshima K; Medical Genetics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan., Urakami K; Cancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan., Nagashima T; SRL Inc., Tokyo, Japan., Kusuhara M; Regional Resources Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan., Sugino T; Division of Pathology, Shizuoka Cancer Center Hospital, Shizuoka, Japan., Mochizuki T; Medical Genetics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan., Yamaguchi K; Office of the President, Shizuoka Cancer Center Hospital, Shizuoka, Japan., Akiyama Y; Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan y.akiyama@scchr.jp.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2017 Mar; Vol. 37 (3), pp. 1321-1328.
DOI:	10.21873/anticanres.11450
Abstrakt:	Background: Project HOPE (High-tech Omics-based Patient Evaluation) has been in progress since 2014 and uses whole-exome sequencing (WES) and gene expression profiling (GEP). Among a total of 1,685 patients with cancer, 13 with melanoma were registered and characterized using multi-omics analyses to investigate specific biomarkers in responders to programmed cell death-1 (PD-1) blockade. Materials and Methods: The patients with melanoma comprised of six males and seven females, and their mean age was 68 years. Five patients were treated with nivolumab, and two were responders. Results: GEP analysis demonstrated that PD-L1 expression was positive in for cases, and melanoma-associated antigens and tumor signaling-associated genes were up-regulated in tumor compared with normal tissues. Additionally, WES analysis indicated more single nucleotide variants (SNVs) per melanoma tumor compared to other tumor types. Remarkably, a case of complete remission after nivolumab therapy showed high expression of PD-L1 protein and the highest number of SNVs. Conclusion: The novel approach used in Project HOPE might be an efficient tool that facilitates identifying specific biomarkers predictive of good responders to anti-PD-1 therapy. (Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu